Download Files:
Ticagrelor-d7
$665 – $1,265
Products Details
Product Description
– Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].
Web ID
– HY-10064S
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C23H21D7F2N6O4S
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016 Dec 8;128(23):2717-2728.|[3]Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015 Jan 1;136(1):234-40.|[4]Sugidachi A, et al. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013 May;169(1):82-9.
CAS Number
– 1265911-55-4
Molecular Weight
– 529.61
SMILES
– N(C1=C2C(N(N=N2)[C@@]3(C[C@H](OCCO)[C@@H](O)[C@H]3O)[H])=NC(SC(C(C([2H])([2H])[2H])([2H])[2H])([2H])[2H])=N1)[C@H]4[C@@](C4)(C5=CC(F)=C(F)C=C5)[H]
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease; Cancer
Solubility
– 10 mM in DMSO
Target
– Isotope-Labeled Compounds;P2Y Receptor
Isoform
– P2Y12 Receptor
Pathway
– GPCR/G Protein;Others
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
